NO831223L - Immunoglobulinpreparater for bruk til behandling av kreft - Google Patents
Immunoglobulinpreparater for bruk til behandling av kreftInfo
- Publication number
- NO831223L NO831223L NO831223A NO831223A NO831223L NO 831223 L NO831223 L NO 831223L NO 831223 A NO831223 A NO 831223A NO 831223 A NO831223 A NO 831223A NO 831223 L NO831223 L NO 831223L
- Authority
- NO
- Norway
- Prior art keywords
- host
- igg
- protein
- cancer
- plasma
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 165
- 238000002360 preparation method Methods 0.000 title claims description 70
- 238000011282 treatment Methods 0.000 title claims description 70
- 108060003951 Immunoglobulin Proteins 0.000 title claims description 62
- 102000018358 immunoglobulin Human genes 0.000 title claims description 62
- 201000011510 cancer Diseases 0.000 title claims description 47
- 102000004169 proteins and genes Human genes 0.000 claims description 164
- 108090000623 proteins and genes Proteins 0.000 claims description 164
- 210000002966 serum Anatomy 0.000 claims description 124
- 238000000034 method Methods 0.000 claims description 78
- 230000027455 binding Effects 0.000 claims description 74
- 230000010412 perfusion Effects 0.000 claims description 60
- 241000282414 Homo sapiens Species 0.000 claims description 46
- 230000000694 effects Effects 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 44
- 230000000295 complement effect Effects 0.000 claims description 40
- 230000001965 increasing effect Effects 0.000 claims description 34
- 229920000392 Zymosan Polymers 0.000 claims description 29
- 239000002244 precipitate Substances 0.000 claims description 29
- 229920001223 polyethylene glycol Polymers 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 108010074605 gamma-Globulins Proteins 0.000 claims description 22
- 230000002476 tumorcidal effect Effects 0.000 claims description 21
- 229930006000 Sucrose Natural products 0.000 claims description 20
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 20
- 238000001962 electrophoresis Methods 0.000 claims description 20
- 239000005720 sucrose Substances 0.000 claims description 20
- 229940072221 immunoglobulins Drugs 0.000 claims description 18
- 241000282465 Canis Species 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 201000008274 breast adenocarcinoma Diseases 0.000 claims description 16
- 210000003743 erythrocyte Anatomy 0.000 claims description 15
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 14
- 229960004397 cyclophosphamide Drugs 0.000 claims description 14
- 238000001556 precipitation Methods 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 12
- 230000020477 pH reduction Effects 0.000 claims description 12
- 230000003171 anti-complementary effect Effects 0.000 claims description 11
- 230000000259 anti-tumor effect Effects 0.000 claims description 11
- 229940127089 cytotoxic agent Drugs 0.000 claims description 11
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 claims description 11
- 230000024203 complement activation Effects 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 230000001419 dependent effect Effects 0.000 claims description 9
- 210000000265 leukocyte Anatomy 0.000 claims description 9
- 210000004698 lymphocyte Anatomy 0.000 claims description 9
- 210000000440 neutrophil Anatomy 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 8
- 231100000433 cytotoxic Toxicity 0.000 claims description 8
- 230000001472 cytotoxic effect Effects 0.000 claims description 8
- 239000013049 sediment Substances 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000002254 cytotoxic agent Substances 0.000 claims description 7
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 230000002285 radioactive effect Effects 0.000 claims description 7
- 102000003896 Myeloperoxidases Human genes 0.000 claims description 6
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229940009456 adriamycin Drugs 0.000 claims description 6
- 238000010166 immunofluorescence Methods 0.000 claims description 6
- 230000007246 mechanism Effects 0.000 claims description 6
- 108010089414 Anaphylatoxins Proteins 0.000 claims description 5
- 241001529936 Murinae Species 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 230000001900 immune effect Effects 0.000 claims description 5
- 230000003033 spasmogenic effect Effects 0.000 claims description 5
- 229920005654 Sephadex Polymers 0.000 claims description 4
- 239000012507 Sephadex™ Substances 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 102000008946 Fibrinogen Human genes 0.000 claims description 3
- 108010049003 Fibrinogen Proteins 0.000 claims description 3
- 206010047141 Vasodilatation Diseases 0.000 claims description 3
- 239000006227 byproduct Substances 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 230000004154 complement system Effects 0.000 claims description 3
- 230000005684 electric field Effects 0.000 claims description 3
- 229940012952 fibrinogen Drugs 0.000 claims description 3
- 230000035931 haemagglutination Effects 0.000 claims description 3
- -1 superoxide anions Chemical class 0.000 claims description 3
- 102000009109 Fc receptors Human genes 0.000 claims description 2
- 108010087819 Fc receptors Proteins 0.000 claims description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims 12
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 1
- 229940027941 immunoglobulin g Drugs 0.000 claims 1
- 230000021962 pH elevation Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 149
- 241000282472 Canis lupus familiaris Species 0.000 description 94
- 239000000047 product Substances 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 102100031506 Complement C5 Human genes 0.000 description 26
- 239000000872 buffer Substances 0.000 description 26
- 238000001802 infusion Methods 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 102100022133 Complement C3 Human genes 0.000 description 16
- 241000282412 Homo Species 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 238000011835 investigation Methods 0.000 description 15
- 230000002269 spontaneous effect Effects 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 239000003610 charcoal Substances 0.000 description 14
- 230000009467 reduction Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 238000005194 fractionation Methods 0.000 description 12
- 208000032839 leukemia Diseases 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 102000006395 Globulins Human genes 0.000 description 10
- 108010044091 Globulins Proteins 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 230000004087 circulation Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000012528 membrane Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 102000004506 Blood Proteins Human genes 0.000 description 6
- 108010017384 Blood Proteins Proteins 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 4
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 102000005600 Cathepsins Human genes 0.000 description 3
- 108010084457 Cathepsins Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010058683 Immobilized Proteins Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 241000295644 Staphylococcaceae Species 0.000 description 3
- 238000010306 acid treatment Methods 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000004660 morphological change Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 238000004848 nephelometry Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000005909 tumor killing Effects 0.000 description 3
- 230000008728 vascular permeability Effects 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 238000011640 AKR mouse Methods 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 2
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 102000005686 Serum Globulins Human genes 0.000 description 2
- 108010045362 Serum Globulins Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011833 dog model Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002497 edematous effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000000909 electrodialysis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000019432 tissue death Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 101800001654 C5a anaphylatoxin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101000693927 Canis lupus familiaris Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010072960 Chest wall tumour Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100039352 Immunoglobulin heavy constant mu Human genes 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 208000034702 Multiple pregnancies Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043391 Thalassaemia beta Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 210000003293 antilymphocyte serum Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 101150004928 bun gene Proteins 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000040 effect on leukemia Effects 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000011043 electrofiltration Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000002977 hyperthermial effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000003282 necrolytic effect Effects 0.000 description 1
- 208000018223 neoplasm of chest wall Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229940085526 tetanus immune globulin Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940041230 varicella-zoster immune globulin Drugs 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36643682A | 1982-04-07 | 1982-04-07 | |
| US47236283A | 1983-03-11 | 1983-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO831223L true NO831223L (no) | 1983-10-10 |
Family
ID=27003359
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO831223A NO831223L (no) | 1982-04-07 | 1983-04-06 | Immunoglobulinpreparater for bruk til behandling av kreft |
| NO841495A NO841495L (no) | 1982-04-07 | 1984-04-13 | Fremgangsmaate for fremstilling av immunoglobulinpreparater for bruk til behandling av kreft |
| NO841498A NO841498L (no) | 1982-04-07 | 1984-04-13 | Fremgangsmaate for fremstilling av et zymosan-aktivert preparat for bruk til behandling av kreft |
| NO841496A NO841496L (no) | 1982-04-07 | 1984-04-13 | Fremgangsmaate for fremstilling av et protein a-igg preparat for bruk ved behandling av kreft |
| NO841497A NO841497L (no) | 1982-04-07 | 1984-04-13 | Fremgangsmaate for fremstilling av et protein a-igg preparat for bruk til behandling av kreft |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO841495A NO841495L (no) | 1982-04-07 | 1984-04-13 | Fremgangsmaate for fremstilling av immunoglobulinpreparater for bruk til behandling av kreft |
| NO841498A NO841498L (no) | 1982-04-07 | 1984-04-13 | Fremgangsmaate for fremstilling av et zymosan-aktivert preparat for bruk til behandling av kreft |
| NO841496A NO841496L (no) | 1982-04-07 | 1984-04-13 | Fremgangsmaate for fremstilling av et protein a-igg preparat for bruk ved behandling av kreft |
| NO841497A NO841497L (no) | 1982-04-07 | 1984-04-13 | Fremgangsmaate for fremstilling av et protein a-igg preparat for bruk til behandling av kreft |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0091784B1 (fr) |
| AU (2) | AU569467B2 (fr) |
| CA (1) | CA1230555A (fr) |
| DE (1) | DE3374756D1 (fr) |
| DK (1) | DK154283A (fr) |
| ES (5) | ES8405621A1 (fr) |
| FI (1) | FI831169L (fr) |
| GB (2) | GB2119803B (fr) |
| GR (1) | GR78514B (fr) |
| NO (5) | NO831223L (fr) |
| PT (1) | PT76505B (fr) |
| RO (3) | RO86661A (fr) |
| ZW (1) | ZW7583A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2161813B (en) * | 1984-07-20 | 1988-07-13 | Michiko Koga | Anti-tumor agent |
| GB9013872D0 (en) * | 1990-06-21 | 1990-08-15 | Inst Tecnologico Y Cientifico | Use of protein a and polypeptide components thereof in the treatment of tumours |
| CA2160155A1 (fr) * | 1993-04-08 | 1994-10-27 | Stella Nowicki | Modele pour l'infection gonococcique |
| GB2422311A (en) * | 2005-01-20 | 2006-07-26 | Martin Lister | Treatment of blood to cure disease |
| DE102005012594A1 (de) | 2005-03-18 | 2006-09-21 | Bayer Technology Services Gmbh | Elektrofiltrationsverfahren |
| SG176064A1 (en) * | 2009-05-14 | 2011-12-29 | Oatmeal Biotechnologies Group L L C | Platform technologies for spontaneously occurring diseases |
| EP4353320A3 (fr) * | 2016-04-28 | 2024-05-15 | Alkahest, Inc. | Utilisation de plasma sanguin et fractions de plasma sanguin en tant que therapie pour lutter contre la croissance et la progression tumorale |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4132769A (en) * | 1974-10-30 | 1979-01-02 | Osther Kurt B | Cancer antigen, cancer therapy, and cancer diagnosis |
| US4146603A (en) * | 1977-02-18 | 1979-03-27 | Research Corporation | Tumor specific glycoproteins and method for detecting tumorigenic cancers |
| FI791551A (fi) * | 1978-05-17 | 1979-11-18 | Benzon As Alfred | Renad cancer associerad protein |
-
1983
- 1983-03-25 AU AU12865/83A patent/AU569467B2/en not_active Ceased
- 1983-03-25 ZW ZW75/83A patent/ZW7583A1/xx unknown
- 1983-04-04 GR GR70987A patent/GR78514B/el unknown
- 1983-04-06 DE DE8383301945T patent/DE3374756D1/de not_active Expired
- 1983-04-06 FI FI831169A patent/FI831169L/fi not_active Application Discontinuation
- 1983-04-06 NO NO831223A patent/NO831223L/no unknown
- 1983-04-06 ES ES521279A patent/ES8405621A1/es not_active Expired
- 1983-04-06 GB GB08309348A patent/GB2119803B/en not_active Expired
- 1983-04-06 RO RO83110576A patent/RO86661A/fr unknown
- 1983-04-06 RO RO83114841A patent/RO89496A/fr unknown
- 1983-04-06 EP EP83301945A patent/EP0091784B1/fr not_active Expired
- 1983-04-06 CA CA000425324A patent/CA1230555A/fr not_active Expired
- 1983-04-06 RO RO83114843A patent/RO89498A/fr unknown
- 1983-04-06 PT PT76505A patent/PT76505B/pt unknown
- 1983-04-07 DK DK154283A patent/DK154283A/da not_active IP Right Cessation
- 1983-12-16 ES ES528121A patent/ES8601703A1/es not_active Expired
- 1983-12-16 ES ES528118A patent/ES528118A0/es active Granted
- 1983-12-16 ES ES528120A patent/ES528120A0/es active Granted
- 1983-12-16 ES ES528119A patent/ES528119A0/es active Granted
-
1984
- 1984-04-13 NO NO841495A patent/NO841495L/no unknown
- 1984-04-13 NO NO841498A patent/NO841498L/no unknown
- 1984-04-13 NO NO841496A patent/NO841496L/no unknown
- 1984-04-13 NO NO841497A patent/NO841497L/no unknown
-
1985
- 1985-04-30 GB GB08510892A patent/GB2163164B/en not_active Expired
-
1988
- 1988-05-04 AU AU15600/88A patent/AU1560088A/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liso et al. | Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma | |
| RU2139092C1 (ru) | Фрагменты антител в терапии | |
| JP5950824B2 (ja) | 抗腫瘍抗体療法を増強するための方法 | |
| US4699783A (en) | Products and methods for treatment of cancer | |
| JP2020147574A (ja) | 炎症及び自己免疫障害を治療するための抗ａｇｅ抗体 | |
| JPH05504554A (ja) | 免疫強化を促進するための方法と組成物 | |
| EP0805871A1 (fr) | Anticorps anti-cd30 prevenant le clivage proteolytique et la liberation de l'antigene cd30 membranaire | |
| NO831223L (no) | Immunoglobulinpreparater for bruk til behandling av kreft | |
| CZ20013270A3 (cs) | Protilátkové a chemokinové konstrukty a jejich pouľití při léčbě autoimunitních chorob | |
| YAMAZAKI et al. | Antibody-dependent macrophage-mediated cytolysis in a murine syngeneic tumor system | |
| Assmann et al. | Comparison of antigenic targets involved in antibody-mediated membranous glomerulonephritis in the mouse and rat. | |
| JPS6053009B2 (ja) | 肝炎ウイルスｂによる急性または慢性の感染治療用の新規医薬 | |
| US4009257A (en) | Preparation of immunosuppressive materials | |
| JPS6127926A (ja) | 細胞毒性薬剤組成物及び細胞毒性薬剤キット | |
| JP7016374B2 (ja) | 悪性の固形および全身性腫瘍の治療、診断および予防において使用するための安定なポリマー状の新規組換えタンパク質ｕｋ１１４ | |
| JPH08509963A (ja) | ＩｇＧ▲下３▼抗体を含む組成物 | |
| CA1242392A (fr) | Produits et methodes pour le traitement du cancer | |
| Cameron et al. | Characterization of the preformed antibodies involved in the xenograft reaction | |
| JPS58201717A (ja) | 腫瘍免疫製剤およびその製造方法 | |
| CA1233748A (fr) | Produits et methodes pour le traitement du cancer | |
| Kumar et al. | Autologous Hsp70 immunization induces anti-tumor immunity and increases longevity and survival of tumor-bearing mice | |
| Griswold et al. | Glomerular localization of antigen and antibody in rabbits following intravenous administration of serum cryoproteins from homologous animals with acute serum sickness | |
| JP2004532261A (ja) | ポリクローナル免疫グロブリンの使用 | |
| TW202237663A (zh) | 抗-t細胞奈米抗體暨其核酸編碼序列及其應用 | |
| De Waal et al. | The role of anti-H-2K and H-2D alloantibodies in enhancement and acute antibody-mediated rejection of mouse skin allografts. |